Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 8
2004 5
2005 9
2006 8
2007 8
2008 3
2009 10
2010 11
2011 5
2012 5
2013 9
2014 9
2015 3
2016 9
2017 14
2018 17
2019 19
2020 27
2021 20
2022 18
2023 13
2024 20
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases.
Gorantla SP, Oelschläger L, Prince G, Osius J, Kolluri SB, Maluje Y, Fähnrich A, Ernst N, Barbosa Gulde A, Ludwig RJ, Gemoll T, Fliedner S, Walter W, Haferlach T, Gebauer N, Busch H, Duyster J, von Bubnoff N. Gorantla SP, et al. Among authors: duyster j. Leukemia. 2025 Apr 23. doi: 10.1038/s41375-025-02594-7. Online ahead of print. Leukemia. 2025. PMID: 40269271
The effect of ibrutinib on the myeloid cell compartment in CNS lymphoma.
Kuehn JC, Neidert NN, Zhang J, Mutter J, Alig S, Klingler C, Hummel F, Ranganathan L, Bleul S, Beck J, Prinz M, Diehn M, Alizadeh A, Duyster J, Sankowski R, Heiland DH, Scherer F. Kuehn JC, et al. Among authors: duyster j. Leukemia. 2025 Apr 10. doi: 10.1038/s41375-025-02600-y. Online ahead of print. Leukemia. 2025. PMID: 40210767 No abstract available.
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity.
Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutmair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson JA, Haferkamp S, Torster L, Kött J, Gebhardt C, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek NP, Singer S, Schmitt-Graeff A, Ceteci F, Greten FR, Blazar BR, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce EL, Meiss F, Becher B, Funke-Lorenz C, Placke JM, Apostolova P, Zeiser R. Braun LM, et al. Among authors: duyster j. Cancer Cell. 2025 Feb 10;43(2):269-291.e19. doi: 10.1016/j.ccell.2025.01.004. Cancer Cell. 2025. PMID: 39933899 Free article. Clinical Trial.
Dynamic evolution of TCF3-PBX1 leukemias at the single-cell level under chemotherapy pressure.
Kusterer M, Lahnalampi M, Voutilainen M, Brand A, Pennisi S, Norona J, Gentile G, Herzog H, Greve G, Lübbert M, Sipola M, Kaartinen E, Sankowski R, Prinz M, Killmer S, Lago MS, Bengsch B, Cysar SR, Aumann K, Werner M, Duyster J, Lohi O, Heinäniemi M, Duque-Afonso J. Kusterer M, et al. Among authors: duyster j. Hemasphere. 2025 Feb 3;9(2):e70071. doi: 10.1002/hem3.70071. eCollection 2025 Feb. Hemasphere. 2025. PMID: 39901941 Free PMC article.
Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.
Shoumariyeh K, Csernalabics B, Salimi Alizei E, Reinscheid M, Giese S, Ciminski K, Kochs G, Schwemmle M, Lang-Meli J, Maas M, Roehlen N, Karl V, Graeser A, Sogukpinar O, von Metzler I, Grathwohl D, Rasche L, Hebart H, Kull M, Emmerich F, Waller CF, Duyster J, Engelhardt M, Hartmann TN, Bengsch B, Boettler T, Neumann-Haefelin C, Hofmann M, Thimme R, Luxenburger H. Shoumariyeh K, et al. Among authors: duyster j. Vaccines (Basel). 2024 Nov 1;12(11):1249. doi: 10.3390/vaccines12111249. Vaccines (Basel). 2024. PMID: 39591152 Free PMC article.
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman UU, Crysandt M, Jost E, Thol F, Heuser M, Götze KS, Schlenk RF, Salih HR, Schittenhelm MM, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kündgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May AM, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M. Bresser H, et al. Among authors: duyster j. Eur J Haematol. 2025 Feb;114(2):231-237. doi: 10.1111/ejh.14304. Epub 2024 Oct 13. Eur J Haematol. 2025. PMID: 39400388 Free PMC article. Clinical Trial.
15-year remission in refractory FLT3-mutated AML attained by sorafenib.
Rummelt C, Pfeifer D, Wäsch R, Zeiser R, Duyster J, Finke J, Lübbert M. Rummelt C, et al. Among authors: duyster j. Ann Hematol. 2024 Nov;103(11):4801-4803. doi: 10.1007/s00277-024-06012-3. Epub 2024 Sep 25. Ann Hematol. 2024. PMID: 39317884 Free PMC article. No abstract available.
Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.
Kuehn JC, Metzger P, Neidert N, Matysiak U, Gräßel L, Philipp U, Bleul S, Pauli T, Falkenstein J, Bertemes H, Cysar S, Hess ME, Frey AV, Duque-Afonso J, Schorb E, Machein M, Beck J, Schnell O, von Bubnoff N, Illert AL, Peters C, Brummer T, Prinz M, Miething C, Becker H, Lassmann S, Werner M, Börries M, Duyster J, Heiland DH, Sankowski R, Scherer F. Kuehn JC, et al. Among authors: duyster j. NPJ Precis Oncol. 2024 Aug 14;8(1):180. doi: 10.1038/s41698-024-00674-y. NPJ Precis Oncol. 2024. PMID: 39143272 Free PMC article.
228 results